Risk of dying from prostate cancer in men randomized to screening differences between: Attendees and nonattendees

Cancer

Volumn 115, Issue 24, 2009, Pages 5672-5679

  Grenabo Bergdahl, Anna ^a,b   Aus, Gunnar ^a   Lilja, Hans ^c,d   Hugosson, Jonas ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Karnsjukhuset   (Sweden)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Diagnosis; Mortality; Patient compliance; Prostate cancer; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER MORTALITY; CANCER SCREENING; DYING; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT;

AGED; ALGORITHMS; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 73149115536     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24680     Document Type: Article

References (20)

1. Linton KD, Hamdy FC. Early diagnosis and surgical management of prostate cancer. Cancer Treat Rev. 2003;29:151-160.
2. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet. 2000;355:1788-1789.
3. Spencer DB, Potter JE, Chung MA, Fulton J, Hebert W, Cady B. Mammographic screening and disease presentation of breast cancer patients who die of disease. Breast J. 2004;10:298-303.
4. Bordas P, Jonsson H, Nystrom L, Cajander S, Lenner P. Early breast cancer deaths in women aged 40-74 years diagnosed during the first 5 years of organised mammography service screening in north Sweden. Breast. 2004;13:276-283.
5. Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97:675-683.
6. Kenter GG, Schoonderwald EM, Koelma IA, Arentz N, Hermans J, Fleuren GJ. The cytological screening history of 469 patients with squamous cell carcinoma of the cervix uteri; does interval carcinoma exist? Acta Obstet Gynecol Scand. 1996;75:400-403.
7. Coldman A, Phillips N, Kan L, Matisic J, Benedet L, Towers L. Risk of invasive cervical cancer after Pap smears: the protective effect of multiple negatives. J Med Screen. 2005;12:7-11.
8. Gleason DF. Urologic Pathology: The Prostate. Philadelphia, PA: Lea & Febiger; 1977.
9. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80:1803-1804.
10. D'Amico AV, Whittington R, Malkowicz SB, et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol. 2001;166:2185-2188.
11. Ichiro T. Healthy screenee bias in evaluating the effectiveness of cancer screening. Jpn J Cancer Clin. 1999;45:1301-1306.
12. Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL. Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care. 2007;45:154-159.
13. Ford ME, Havstad SL, Fields ME, Manigo B, McClary B, Lamerato L. Effects of baseline comorbidities on cancer screening trial adherence among older African American men. Cancer Epidemiol Biomarkers Prev. 2008;17:1234-1239.
14. Lipscombe LL, Hux JE, Booth GL. Reduced screening mammography among women with diabetes. Arch Intern Med. 2005;165:2090-2095.
15. Cuzick J, Edwards R, Segnan N. Adjusting for noncompliance and contamination in randomized clinical trials. Stat Med. 1997;16:1017-1029.
16. Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59:311-318.
17. Spencer DB, Potter JE, Chung MA, Fulton J, Hebert W, Cady B. Mammographic screening and disease presentation of breast cancer patients who die of disease. Breast J. 2004;10:298-303.
18. Roobol MJ, Grenabo A, Schroder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst. 2007;99:1296-1303.
19. Spencer DB, Potter JE, Chung MA, Fulton J, Hebert W, Cady B. Mammographic screening and disease presentation of breast cancer patients who die of disease. Breast J. 2004;10:298-303.
20. Zackrisson S, Janzon L, Manjer J, Andersson I. Improved survival rate for women with interval breast cancer - results from the breast cancer screening programme in Malmo, Sweden 1976-1999. J Med Screen. 2007;14:138-143.